Drugs & Aging

, Volume 15, Issue 6, pp 429–437 | Cite as

Treatment of Nocturia in the Elderly

  • Henrique E. Kallas
  • Jirayos Chintanadilok
  • Javier Maruenda
  • James L. Donahue
  • David T. Lowenthal
Disease Management

Abstract

The aging process, behavioural habits and a multitude of pathological conditions are the main contributors to the development of nocturia in the elderly. Age-related physiological changes can alter the regular pattern of urine excretion and lead to increased nocturnal frequency of voiding. In addition, aging is associated with anatomical and physiological changes of the urinary tract itself that predispose to increased urinary frequency without affecting urine volume.

Several urinary and extra-urinary tract conditions may have nocturia as a prominent symptom. These conditions can be grouped as those associated with bladder overactivity, bladder outlet obstruction, bladder hypotonicity and an increased urine volume. A detailed assessment that gathers clues from the medical history, physical examination and laboratory is of utmost importance in identifying the specific causes.

Overactive bladder can be idiopathic or associated with different triggers such as UTI, bladder stones, bladder tumours and CNS diseases that disrupt the normal inhibitory signals to the bladder. It may be cured by the successful elimination of the trigger conditions. Therapeutic modalities include behavioural therapies with scheduled voiding, anticholinergic drugs and in women the use of transvaginal electrical stimulation.

Benign prostatic hyperplasia is the most common cause of bladder outlet obstruction in men. Different drug classes (e.g. peripheral α-adrenoceptor blockers and 5 α-reductase inhibitors) are now available for the treatment of mild to moderate symptoms. Surgery is reserved for patients with severe symptoms or with complications, with new and less invasive surgical techniques being preferred.

Bladder hypotonicity is usually caused by peripheral neuropathies, spinal cord lesions and the indiscriminate use of drugs with anticholinergic actions. Treatment involves discontinuation of implicated drugs, short term use of cholinergic drugs and urinary catheterisation.

Increased urine volumes and nocturia are frequently seen in hyperosmolar and oedematous states. Excessive ingestion of fluids, caffeinated or alcoholic beverages are habits that commonly produce nocturia. Although more definitive studies are awaited, low dose loop diuretics given a few hours prior to bedtime and desmopressin nasal spray or tablets may be useful alternatives for the control of nocturic symptoms in elderly patients with nocturnal polyuria syndrome.

Whenever nocturia is present, clinicians should try to identify its causes by means of a thorough history, physical examination and pertinent complimentary tests. Once the specific cause or causes are found, most cases can be satisfactorily managed with behavioural, pharmacological or surgical therapies.

Keywords

Adis International Limited Benign Prostatic Hyperplasia Atrial Natriuretic Peptide Overactive Bladder Finasteride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Malmsten UG, Milsom I, Molander U, et al. Urinary incontinence and lower urinary tract symptoms: an epidemiological study of men aged 45 to 99 years. J Urol 1997; 158 (5): 1733–7PubMedCrossRefGoogle Scholar
  2. 2.
    Saito M, Kondo A, Kato T, et al. Frequency-volume charts: comparison frequency between elderly and adult patients. Br J Urol 1993; 72: 38–41PubMedCrossRefGoogle Scholar
  3. 3.
    Asplund R, Aberg HE. Micturition habits of older people, voiding frequency and urine volumes. Scand J Urol Nephrol 1992; 26: 345–9PubMedCrossRefGoogle Scholar
  4. 4.
    Kirkland JL, Lye M, Levy DW, et al. Patterns of urine flow and electrolyte excretion in healthy elderly people. BMJ 1983; 287: 1665–7PubMedCrossRefGoogle Scholar
  5. 5.
    Ouslander J, Schnelle J, Simmons S, et al. The dark side of incontinence: nighttime incontinence in nursing home residents. J Am Geriatr Soc 1993; 41: 371–6PubMedGoogle Scholar
  6. 6.
    Asplund R. The nocturnal polyuria syndrome (NPS). Gen Pharmacol 1995; 26: 1203–9PubMedCrossRefGoogle Scholar
  7. 7.
    Lindeman RD. Renal and urinary tract function. In: Masoro EJ, editor. Aging. New York (NY): Oxford Press, 1995: 485–504Google Scholar
  8. 8.
    Donahue JL, Lowenthal DT. Nocturnal polyuria in the elderly person. Am J Med Sci 1997; 314: 232–38PubMedCrossRefGoogle Scholar
  9. 9.
    Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med 1991; 229: 131–4PubMedCrossRefGoogle Scholar
  10. 10.
    Standaert DG, Cechetto DF, Needleman P, et al. Inhibition of the firing of vasopressin neurons by atriopeptin. Nature 1987; 329: 151–3PubMedCrossRefGoogle Scholar
  11. 11.
    Needleman P, Greenwald JE. Atriopeptin: a cardiac hormone intimately involved in fluid, electrolyte, and blood-pressure homeostasis. N Engl J Med 1986; 314: 828–34PubMedCrossRefGoogle Scholar
  12. 12.
    Tan T, Hoefnagels W, Swinkels LM, et al. The effect of volume expansion on atrial natriuretic peptide and cyclic guanosine monophosphate levels in young and aged subjects. J Am Geriatr Soc 1990; 38: 1215–9PubMedGoogle Scholar
  13. 13.
    Haller BG, Zust H, Shaw S, et al. Effects of posture and ageing on circulating atrial natriuretic peptide levels in man. J Hypertens 1987; 5: 551–6PubMedCrossRefGoogle Scholar
  14. 14.
    Ohashi M, Fujio N, Nawata H, et al. High plasma concentrations of human atrial natriuretic polypeptide in aged men. J Clin Endocrinol Metab 1987; 64: 81–5PubMedCrossRefGoogle Scholar
  15. 15.
    Quay W. Diffuse endocrine and chemical mediators. In: Timiras P, Quay W, Vernadakis A, editors. Hormones and aging. Boca Raton (FL): CRC Press, 1995: 107–20Google Scholar
  16. 16.
    Resnick NM. Voiding dysfunction in the elderly. In: Yalla SV, McGuire EJ, Elbadawi A, et al, editors. Neurourology and urodynamics: principles and practice. New York (NY): Macmillan Publishing Co. Inc., 1988: 303–30Google Scholar
  17. 17.
    Diokno AC, Brown MB, Brock BM, et al. Clinical and cystometric characteristics of continent and incontinent noninstitutionalized elderly. J Urol 1998; 140: 567–71Google Scholar
  18. 18.
    Resnick NM. Urinary incontinence in older adults. Hosp Pract 1992; 27 (10): 552–66Google Scholar
  19. 19.
    Mold JW. Pharmacotherapy of urinary incontinence. Am Fam Physician 1996; 54: 673–80PubMedGoogle Scholar
  20. 20.
    Burgio KL, Locher JL, Ives DG, et al. Nocturnal enuresis in community-dwelling older adults. J Am Geriatr Soc 1996; 44 (2): 139–43PubMedGoogle Scholar
  21. 21.
    Fantl JA, Wyman JF, Harkins SW, et al. Bladder training in the management of lower urinary tract dysfunction in women: a review. J Am Geriatr Soc 1990; 38: 329–32PubMedGoogle Scholar
  22. 22.
    Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991; 265: 609–13PubMedCrossRefGoogle Scholar
  23. 23.
    Brubaker L, Benson JT, Bent A, et al. Transvaginal electrical stimulation for female urinary incontinence. Am J Obstet Gynecol 1997; 177: 536–40PubMedCrossRefGoogle Scholar
  24. 24.
    Gibaldi M, Grundhofer B. Biopharmaceutical influences on the anticholinergic effects of propantheline. Clin Pharmacol Ther 1975; 18: 457–61PubMedGoogle Scholar
  25. 25.
    Moore KH, Hay DM, Imrie AE, et al. Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br J Urol 1990; 66: 479–85PubMedCrossRefGoogle Scholar
  26. 26.
    Castleden CM, Duffin HM, Gulati RS. Double blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 1986; 15: 299–303PubMedCrossRefGoogle Scholar
  27. 27.
    Lose G, Jorgensen L, Thunedborg P. Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study. J Urol 1989; 142: 1024–6PubMedGoogle Scholar
  28. 28.
    Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hyperplasia in the community. Lancet 1991; 338: 469–71PubMedCrossRefGoogle Scholar
  29. 29.
    Chutka DS, Takahashi PY. Urinary incontinence in the elderly: drug treatment options. Drugs 1998; 56: 587–95PubMedCrossRefGoogle Scholar
  30. 30.
    Gillenwater JY, Conn RL, Chrysant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebocontrolled, dose-response multicenter study. J Urol 1995; 154: 110–5PubMedCrossRefGoogle Scholar
  31. 31.
    Lepor H, Auerbach S, Puras-Baez A, et al. Arandomized, placebocontrolled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 1992; 148: 1467–74PubMedGoogle Scholar
  32. 32.
    Noble AJ, Chess-Williams R, Couldwell C, et al. The effects of tamsulosin, a high affinity antagonist at functional alpha 1A and alpha 1D-adrenoceptor subtypes. Br J Pharmacol 1997; 120: 231–8PubMedCrossRefGoogle Scholar
  33. 33.
    Chapple CR, Baert L, Thind P, et al. Tamsulosin 0.4mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of BPH (symptomatic BPH), the European Tamsulosin Study Group. Eur Urol 1997; 32 (4): 462–70PubMedGoogle Scholar
  34. 34.
    Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with BPH: pharmacodynamic effect. Clin Ther 1997; 19 (4): 730–42PubMedCrossRefGoogle Scholar
  35. 35.
    Lowenthal DT, Maruenda J, Chintanadilok J, et al. Clinical pharmacology-physiology conference: the hypertensive elderly male with prostatism. Geriatr Nephrol Urol 1999; 9: 57–60PubMedCrossRefGoogle Scholar
  36. 36.
    Moore E, Bracken B, Bremner W, et al. Proscar: five year experience. Eur Urol 1995; 28: 304–9PubMedGoogle Scholar
  37. 37.
    Boyle P, Gould AL. Prostate volume predicts outcome of treatment of BPH with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398–405PubMedCrossRefGoogle Scholar
  38. 38.
    Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533–9PubMedCrossRefGoogle Scholar
  39. 39.
    Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995; 345: 1529–32PubMedCrossRefGoogle Scholar
  40. 40.
    Lowe FC, Ku JC. Phytotherapy of benign prostatic hyperplasia: a critical review. Urology 1996; 48 (1): 12–20PubMedCrossRefGoogle Scholar
  41. 41.
    Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology 1999; 53 (3 Suppl. 3a): 1–6PubMedCrossRefGoogle Scholar
  42. 42.
    Chutka DS, Fleming KC, Evans MP, et al. Urinary incontinence in the elderly population. Mayo Clin Proc 1996; 71: 93–101PubMedCrossRefGoogle Scholar
  43. 43.
    Ulfberg J, Thuman R. A non-urologic cause of nocturia and enuresis-obstructive sleep apnea syndrome (OSAS). Scand J Urol Nephrol 1996; 30 (2): 135–7PubMedCrossRefGoogle Scholar
  44. 44.
    Krieger J. Mechanisms of daytime pulmonary hypertension and altered renal function in obstructive sleep apnea. In: Guilleminault C, Partinen M, editors. Obstructive sleep apnea syndrome: clinical research and treatment. New York (NY): Raven Press, 1990: 71–9Google Scholar
  45. 45.
    Reynard JM, Cannon A, Yang Q, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol 1998; 81: 215–8PubMedCrossRefGoogle Scholar
  46. 46.
    Pedersen PA, Johansen PB. Prophylactic treatment of adult nocturia with bumetanide. Br J Urol 1998; 62 (2): 145–7CrossRefGoogle Scholar
  47. 47.
    Physician’s desk reference. Oradell (NJ): Medical Economics, 1997: 2180–2Google Scholar
  48. 48.
    Eckford SD, Swami KS, Jackson SR, et al. Desmopressin in the treatment of nocturia and enuresis in patients with multiple sclerosis. Br J Urol 1994; 74: 738–5Google Scholar
  49. 49.
    Valiquette G, Abrams GM, Herbert J. DDAVP in the management of nocturia in multiple sclerosis [letter]. Ann Neurol 1992; 31: 577PubMedCrossRefGoogle Scholar
  50. 50.
    Hilton P, Hertogs K, Stanton SL. The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 1983; 46: 854–5PubMedCrossRefGoogle Scholar
  51. 51.
    Eckford SD, Carter PG, Jackson SR, et al. An open, in-patient incremental safety and efficacy study of desmopressin in women with multiple sclerosis and nocturia. Br J Urol 1995; 76: 459–63PubMedCrossRefGoogle Scholar
  52. 52.
    Mathias CJ, Fosbraey P, Da CD, et al. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. BMJ 1986; 293: 353–4PubMedCrossRefGoogle Scholar
  53. 53.
    Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson’s disease. Mov Disord 1995; 10: 337–40PubMedCrossRefGoogle Scholar
  54. 54.
    Mansson W, Sundin T, Gullberg B. Evaluation of a synthetic vasopressin analogue for treatment of nocturia in benign prostatic hypertrophy: a double-blind study. Scand J Urol Nephrol 1980; 14: 139–41PubMedCrossRefGoogle Scholar
  55. 55.
    Hilton P, Stanton SL. The use of desmopressin (DDAVP) in nocturnal urinary frequency in the female. Br J Urol 1982; 54: 252–5PubMedCrossRefGoogle Scholar
  56. 56.
    Asplund R, Sundberg B, Bengtsson P. Desmopressin for the treatment of nocturnal polyuria in the elderly subjects: a dose titration study. Br J Urol 1998; 82: 642–6PubMedCrossRefGoogle Scholar
  57. 57.
    Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in 60–74 year old subjects: a double-blind, placebo-controlled and randomised exploratory study. Br J Urol 1999; 83: 591–5Google Scholar
  58. 58.
    Carter PG, McConnell AA, Abrams P. The safety and efficacy of DDAVP in the elderly. Neurourol Urodyn 1992; 11: 421–2Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Henrique E. Kallas
    • 1
  • Jirayos Chintanadilok
    • 1
  • Javier Maruenda
    • 1
  • James L. Donahue
    • 1
  • David T. Lowenthal
    • 1
  1. 1.Geriatric Research, Education and Clinical Center (182)Veterans Affairs Medical CenterGainesvilleUSA

Personalised recommendations